Sign inCreate account

Report workspace

Add to folder
NCT07040280NOT_YET_RECRUITINGanonymous

A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

Sponsor

Source record

Eastern Cooperative Oncology Group

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

Sulforaphane, a compound derived from cruciferous vegetables, primarily broccoli, known for its potential anti-cancer properties through mechanisms such as antioxidant activity and modulation of cellular signaling pathways.

Indication / condition

AI-normalized

Melanoma

Intervention

Source record

Sulforaphane (broccoli sprout extract), Placebo, Derma-AI

Source & freshness

Source record

NCT ID

NCT07040280

Original source

ClinicalTrials.gov

Source last updated

Jun 27, 2025

Ingested at

Jun 13, 2026

Internal sync

Jun 13, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT07040280

Title

A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

Sponsor

Eastern Cooperative Oncology Group

Status

NOT_YET_RECRUITING

Phase

Phase 2

Condition raw

Melanoma

Condition normalized

Melanoma

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Sulforaphane, a compound derived from cruciferous vegetables, primarily broccoli, known for its potential anti-cancer properties through mechanisms such as antioxidant activity and modulation of cellular signaling pathways.

Target normalized

Sulforaphane, a compound derived from cruciferous vegetables, primarily broccoli, known for its potential anti-cancer properties through mechanisms such as antioxidant activity and modulation of cellular signaling pathways.

Interventions

Sulforaphane (broccoli sprout extract), Placebo, Derma-AI

Public preview

Source record

The Phase II trial sponsored by the Eastern Cooperative Oncology Group aims to evaluate the efficacy of sulforaphane in preventing melanoma in patients with multiple atypical nevi and a history of melanoma. If successful, this trial could position sulforaphane as a novel preventive treatment in the dermatological oncology market, which is increasingly focused on personalized and preventive strategies. The competitive landscape includes existing melanoma therapies and emerging preventive agents, necessitating a thorough analysis of sulforaphane's market entry strategy and potential partnerships. Given the increasing incidence of melanoma and the demand for effective preventive measures, this asset could attract significant interest from pharmaceutical companies and investors. Diligence should focus on the trial's design, patient recruitment strategies, and the robustness of the data generated.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase II Double-Blind Trial of Sulforaphane for Therapeutic Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT07040280

Status

NOT_YET_RECRUITING

Phase

Phase 2

Sponsor

Eastern Cooperative Oncology Group

Executive brief

Investment-Ready Snapshot

The Phase II trial sponsored by the Eastern Cooperative Oncology Group aims to evaluate the efficacy of sulforaphane in preventing melanoma in patients with multiple atypical nevi and a history of melanoma. If successful, this trial could position sulforaphane as a novel preventive treatment in the dermatological oncology market, which is increasingly focused on personalized and preventive strategies. The competitive landscape includes existing melanoma therapies and emerging preventive agents, necessitating a thorough analysis of sulforaphane's market entry strategy and potential partnerships. Given the increasing incidence of melanoma and the demand for effective preventive measures, this asset could attract significant interest from pharmaceutical companies and investors. Diligence should focus on the trial's design, patient recruitment strategies, and the robustness of the data generated.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJun 27, 2025
Internal syncJun 13, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07040280

Indication

Melanoma

Modality

small molecule

Target

Sulforaphane, a compound derived from cruciferous vegetables, primarily broccoli, known for its potential anti-cancer properties through mechanisms such as antioxidant activity and modulation of cellular signaling pathways.

Intervention

Sulforaphane (broccoli sprout extract), Placebo, Derma-AI

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.